AUTHOR=Chirchiglia Domenico , Cione Erika , Caroleo Maria C. , Wang Minyan , Di Mizio Giulio , Faedda Noemi , Giacolini Teodosio , Siviglia Serena , Guidetti Vincenzo , Gallelli Luca 

TITLE=Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

JOURNAL=Frontiers in Neurology

VOLUME=9

YEAR=2018

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2018.00674

DOI=10.3389/fneur.2018.00674

ISSN=1664-2295

ABSTRACT=<p><bold>Background:</bold> Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs.</p><p><bold>Methods:</bold> A total of 20 patients, 8 male (33–56-years, average 41.4 ± 7.8) and 12 female (19–61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment.</p><p><bold>Results:</bold> umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male <italic>P</italic> = 0.01189; female <italic>P</italic> = &lt;0.01) and they lasted until the end of the study (male <italic>P</italic> = 0.0066; female <italic>P</italic> = 0.01473).</p><p><bold>Conclusion:</bold> Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.</p>